TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Dividend Updates
Board Recommended to the members a final dividend of ? 8/- (160%) per equity share of ? 5 each. The final dividend amount, if declared by the Shareholders, is proposed to be paid / dispatched on or around 14th August, 2023. Earlier an interim dividend of ? 14/- (280%) per equity share was paid during the last quarter. TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Outcome for Disclosure Pursuant To Regulation 30 Read With Schedule III And Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements), 2015, ("Listing Regulations")
Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), 2015, ("Listing Regulations") TORRENT PHARMACEUTICALS LTD. - 500420 - Disclosure Pursuant To Regulation 30 Read With Schedule III And Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements), 2015, ("Listing Regulations")
Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), 2015, ("Listing Regulations") TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 08-Feb-19 and BSE and NSE Circulars dated 16-Mar-23 and 10-Apr-23 respectively, kindly find enclosed herewith Annual Secretarial Compliance Report for the year ended on 31-Mar-23 issued by M/s. M. C. Gupta & Co., Practicing Company Secretaries, Ahmedabad. Kindly take note of the above. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
We would like to inform that Hon''ble National Company Law Tribunal, Ahmedabad Bench ("NCLT"), vide its Order dated 17th May, 2023, has sanctioned the Scheme of Arrangement in the nature of Amalgamation between Curatio Health Care (I) Private Limited, a wholly owned subsidiary of the Company with Torrent Pharmaceuticals Limited and their respective shareholders and creditors ("Scheme") pursuant to the provisions of Section 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules made thereunder. A copy of the said Order is available on the website of the Company. The above is in continuation to our earlier communication dated 21-Dec-22 intimating the approval of the said Scheme of Amalgamation by the Board of Directors of the Company in its meeting held on 21-Dec-22. The Scheme will become effective upon filing of the said Order with the Registrar of Companies, Gujarat. Kindly take note of the above.
Torrent Pharma forms Bullish Harami pattern. Will it reclaim record high?
After hitting a high around Rs 1,680, the stock has been into consolidation for more than couple of weeks and has been struggling for breakout the same high. If the said level breaks out in coming days, then the stock can march towards its record high of Rs 1,750, experts feel. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Post Quarterly Financial Result Conference call with investors / analyst We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 30th May, 2023 at 06:00 P.M. to discuss the financial performance of the Company for the quarter and year ended 31st March, 2023. TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 ,inter alia, to consider and approve We would like to inform you that: 1. A meeting of the Board of Directors will be held on Tuesday, 30-May-23, inter alia, to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-23. 2. In the above meeting, the Board would also consider the following: i. Recommendation of final dividend, if any, on the equity shares of the Company, for the year 2022-23. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors, the said item will be placed for Shareholders'' approval in the ensuing Annual General Meeting. Kindly take note of the above.